VTRS logo

Viatris Inc.

VTRS
Healthcare|Drug Manufacturers - Specialty & Generic|US
$19.91
+0.94 (+4.96%)
DCF Value
$19.78
Cash / Share
$1.65
Next Earnings Report
Feb 25, 2027
EPS est. $0.60 · Revenue est. $3.72B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Jun 15, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (12)

Nov 2026
Est. completion
P2Contraception
Investigating Ovulation Inhibition for Use as a Contraceptive
Dec 2026
Est. completion
P4Dry Eye
Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
Dec 2026
Est. completion
P3Lupus Erythematosus, Systemic
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Jan 2027
Est. completion
P4Erectile Dysfunction Following Radical Prostatectomy
PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)
Mar 2027
Est. completion
Cancer
Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Experience
Mar 2027
Est. completion
P3Lupus Erythematosus, Systemic
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
May 2027
Est. completion
P3Female Contraception
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
Jun 2027
Est. completion
P4COPD (Chronic Obstructive Pulmonary Disease)
Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
Oct 2027
Est. completion
P2SLE - Systemic Lupus Erythematosus
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
Nov 2027
Est. completion
P1P2Neurotrophic Keratopathy
A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in Participants With Stage 1 or 2 Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy
Aug 2029
Est. completion
P3Nephritis, Lupus
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Aug 2030
Est. completion
P3MDR-TB
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
NCT06052995
Apr 2025
Impairments That Affect Correct Inhaler Use in COPD
NCT06135324

SEC Filings (60)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 30, 2026SC TO-TTender offerDocumentIndex
Oct 8, 2026SC TO-CTender offerDocumentIndex
Oct 8, 2026SC TO-CTender offerDocumentIndex
Oct 8, 20268-KMaterial eventDocumentIndex
Sep 8, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 1, 20268-KMaterial eventDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
Jun 15, 2026424B5Offering prospectusDocumentIndex
Jun 12, 2026FWPDocumentIndex
Jun 12, 2026424B5Offering prospectusDocumentIndex
May 15, 20268-KMaterial eventDocumentIndex
May 7, 202610-QQuarterly reportDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
May 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 2, 2026ARSAnnual report to holdersDocumentIndex
Apr 2, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 2, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 4, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 3, 20268-KMaterial eventDocumentIndex
Dec 8, 20258-KMaterial eventDocumentIndex
Dec 5, 20258-KMaterial eventDocumentIndex
Dec 5, 20258-K/AMaterial eventDocumentIndex
Nov 10, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 6, 202510-QQuarterly reportDocumentIndex
Nov 6, 20258-KMaterial eventDocumentIndex
Oct 24, 20258-KMaterial eventDocumentIndex
Oct 24, 2025ARSAnnual report to holdersDocumentIndex